Significantly prolongs the life of prostate cancer patients Novartis targeted radiotherapy reaches phase 3 clinical endpoint

On March 23, Novartis announced that its potential "first-in-class" targeted radioligand therapy (RLT) 177Lu-PSMA-617 reached the dual primary endpoint in a phase 3 clinical trial for the treatment of patients with advanced prostate cancer .

Prostate cancer is the second most common type of tumor in men worldwide.

Radioligand therapy combines radioisotopes with molecules that can bind to specific biomarkers expressed by tumors.

Previously, radiotherapy of cancer has always used external radiation delivery as the main treatment method.

177Lu-PSMA-617 is a radioligand therapy candidate obtained by Novartis in 2018 when it acquired Endocyte for US$2.

In a randomized, open-label phase 3 clinical trial called VISION, patients with PSMA-positive mCRPC received 177Lu-PSMA-617 or the best standard therapy.

"The 5-year survival rate of mCRPC patients is less than one-sixth, and they urgently need new treatment options.

Reference materials:

[1] Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostatecancer.

[2] Novartis Oncology Pipeline Update.